Medivation announced the completion of patient enrollment in its Phase 3 trial of MDV3100 for the treatment of advanced prostate cancer. This randomized, placebo-controlled, double-blind, multi-national trial (known as AFFIRM) enrolled 1199 patients at sites around the world. The primary endpoint of the trial is overall survival; secondary endpoints include progression-free survival, safety and tolerability. This study will evaluate MDV3100 at a dose of 160mg/day versus placebo in patients with advanced prostate cancer who have previously been treated with chemotherapy.
MDV3100 is a triple-acting oral novel androgen receptor antagonist.
For more information please call (415) 543-3470 or visit www.medivation.com.